HER2-Targeted Antibody-Drug Conjugate Toxicities in Breast Cancer.

ABSTRACT:

Background

HER2-targeted antibody-drug conjugates (ADCs) have dramatically advanced breast cancer outcomes. Two HER2-targeted ADCs, trastuzumab deruxtecan and trastuzumab emtansine, are currently approved for use in breast cancer, with > 60 other candidates under ongoing investigation.

Methods

In this report, we provide a narrative review of existing data underlying the current understanding of HER2-targeted ADC toxicities in breast cancer, highlighting both common and serious adverse events.

Results

When used as an adjuvant or neoadjuvant, first- or second-line agent, alone or in combination with another agent, trastuzumab emtansine has been commonly associated with epistaxis, fatigue, headache, nausea, and pyrexia across several clinical trials. Comparatively, trast

SUBMITTER: Lee S 

PROVIDER: S-EPMC12685761 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature